Trailing Twelve Months Revenue Growth: inovio.com (INO)

Inovio Pharmaceuticals (INO) strategy for implementing DNA therapy against infections drives the TTM annual revenue dynamics on the GURU.Markets terminal chart, where the value has settled at 63.70. The company's pricing power is based on the unique Cellectra device, although ultimate success depends on regulatory approval and the effective funding of R&D projects.
Inovio - analytical breakdowns and key metrics (INO)

This indicator measures the percentage change in revenue over a rolling 12-month period, allowing investors to quickly assess the commercial resilience of the business between quarterly reports. Analyzing the 12-month YoY revenue growth rate is critical for Inovio Pharmaceuticals (INO), as it reflects the market monetization of the Cellectra platform and the success of regulatory approvals for new DNA vaccines amid macroeconomic volatility.